Tectonic Therapeutic Inc. Reports Q3 2024 Results [Yahoo! Finance]
Tectonic Therapeutic, Inc. (TECX)
Company Research
Source: Yahoo! Finance
Tectonic Therapeutic Inc., based in Watertown, Massachusetts, is a clinical-stage biotechnology company specializing in the development of therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) to address unmet medical needs. Tectonic recently announced its third-quarter 2024 financial results, highlighting significant advancements in its clinical pipeline, including ongoing trials and a strong cash position. The company has made remarkable progress in its clinical trials, with patient enrollment in the Phase 1b hemodynamic trial exceeding expectations and the APEX Phase 2 clinical trial for its lead program, TX45, underway. Additionally, Tectonic selected TX2100 as the development candidate for its second program targeting Hereditary Hemorrhagic Telangiectasia (HHT), a genetic bleeding disorder with no approved therapies. Tectonic's financial performance for the third quarter of 2024 shows an increase in research and development expenses to $14.3 milli
Show less
Read more
Impact Snapshot
Event Time:
TECX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECX alerts
High impacting Tectonic Therapeutic, Inc. news events
Weekly update
A roundup of the hottest topics
TECX
News
- Tectonic Therapeutic (NASDAQ: TECX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $65.00 price target on the stock.MarketBeat
- Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $55.00 to $79.00. They now have an "overweight" rating on the stock.MarketBeat
- Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Leerink Partners from $49.00 to $69.00. They now have an "outperform" rating on the stock.MarketBeat
- Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion ProteinGlobeNewswire
- Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
TECX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/7/24 - Form 8-K
- TECX's page on the SEC website